T1	Participants 50 63	COPD patients
T2	Participants 259 277	subjects with COPD
T3	Participants 523 657	placebo-controlled clinical trial of triamcinolone acetonide (1200 microg daily) vs placebo in participants with mild-to-moderate COPD
T4	Participants 757 775	1,116 participants
T5	Participants 839 852	1,116 smokers
T6	Participants 856 900	recent ex-smokers with mild-to-moderate COPD
T7	Participants 1453 1479	Older men in the ICS group
